Vincent Ganière1, François Feihl, Damien Tagan. 1. Hôpital Riviera, Site du Samaritain, Département de Médecine Interne, Boulevard Paderewski 5, 1800, Vevey, Switzerland.
Abstract
OBJECTIVE: Sildenafil has a well established pulmonary vasodilatory effect, but has seldom been used in critically ill patients. We report a case of severe recurrent pulmonary embolism in which sildenafil was used as a rescue therapy. RESULTS: After oral administration of 50 mg of sildenafil, cardiac index increased from 2.11/min/m(2) to 3.21/min/m(2); mean pulmonary artery pressure decreased from 56 mmHg to 46 mmHg, and pulmonary vascular resistance index decreased from 700 dynes/cm(-5)/m(2) to 425 dynes/cm(-5)/m(2), without reduction of arterial systemic pressure. Clinical condition also improved during the following days under treatment of 50 mg sildenafil three times daily. CONCLUSIONS: These observations should stimulate studies with sildenafil in the ICU setting. Sildenafil is easy to administer in every ICU and at any time. If its potential is confirmed, it may be a life-saving drug in some emergency situations caused by severe pulmonary hypertension.
OBJECTIVE:Sildenafil has a well established pulmonary vasodilatory effect, but has seldom been used in critically ill patients. We report a case of severe recurrent pulmonary embolism in which sildenafil was used as a rescue therapy. RESULTS: After oral administration of 50 mg of sildenafil, cardiac index increased from 2.11/min/m(2) to 3.21/min/m(2); mean pulmonary artery pressure decreased from 56 mmHg to 46 mmHg, and pulmonary vascular resistance index decreased from 700 dynes/cm(-5)/m(2) to 425 dynes/cm(-5)/m(2), without reduction of arterial systemic pressure. Clinical condition also improved during the following days under treatment of 50 mg sildenafil three times daily. CONCLUSIONS: These observations should stimulate studies with sildenafil in the ICU setting. Sildenafil is easy to administer in every ICU and at any time. If its potential is confirmed, it may be a life-saving drug in some emergency situations caused by severe pulmonary hypertension.
Authors: L Zhao; N A Mason; N W Morrell; B Kojonazarov; A Sadykov; A Maripov; M M Mirrakhimov; A Aldashev; M R Wilkins Journal: Circulation Date: 2001-07-24 Impact factor: 29.690
Authors: Carlos A Dias-Junior; Tadeu F Vieira; Heitor Moreno; Paulo R Evora; Jose E Tanus-Santos Journal: Pulm Pharmacol Ther Date: 2005-01-20 Impact factor: 3.410
Authors: Hossein A Ghofrani; Frank Reichenberger; Markus G Kohstall; Eike H Mrosek; Timon Seeger; Horst Olschewski; Werner Seeger; Friedrich Grimminger Journal: Ann Intern Med Date: 2004-08-03 Impact factor: 25.391
Authors: Hossein A Ghofrani; Robert Voswinckel; Frank Reichenberger; Horst Olschewski; Peter Haredza; Burcu Karadaş; Ralph T Schermuly; Norbert Weissmann; Werner Seeger; Friedrich Grimminger Journal: J Am Coll Cardiol Date: 2004-10-06 Impact factor: 24.094
Authors: Ghada W Mikhail; Sanjay K Prasad; Wei Li; Paula Rogers; Adrian H Chester; Stephanie Bayne; David Stephens; Mohammed Khan; J S R Gibbs; Timothy W Evans; Andrew Mitchell; Magdi H Yacoub; Michael A Gatzoulis Journal: Eur Heart J Date: 2004-03 Impact factor: 29.983
Authors: Karina Lidianne Alcântara Saraiva; Amanda Karolina Soares E Silva; Maria Inês Wanderley; Araken Almeida De Araújo; José Roberto Botelho De Souza; Christina Alves Peixoto Journal: Int J Exp Pathol Date: 2009-08 Impact factor: 1.925
Authors: Carol Reinero; Lance C Visser; Heidi B Kellihan; Isabelle Masseau; Elizabeth Rozanski; Cécile Clercx; Kurt Williams; Jonathan Abbott; Michele Borgarelli; Brian A Scansen Journal: J Vet Intern Med Date: 2020-02-17 Impact factor: 3.333